ONC
BeiGene Ltd - ADR

2,039
Mkt Cap
$32.46B
Volume
179,668.00
52W High
$385.22
52W Low
$170.99
PE Ratio
613.81
ONC Fundamentals
Price
$319.06
Prev Close
$320.84
Open
$320.84
50D MA
$331.11
Beta
0.67
Avg. Volume
336,475.95
EPS (Annual)
-$6.13
P/B
8.55
Rev/Employee
$346,559.28
Loading...
Loading...
News
all
press releases
35,910 Shares in BeOne Medicines Ltd. - Sponsored ADR $ONC Purchased by Axa S.A.
Axa S.A. bought a new stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Nave Chronic Lymphocytic Leukemia
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth...
Business Wire·5d ago
News Placeholder
Temasek Holdings Private Ltd Acquires New Position in BeOne Medicines Ltd. - Sponsored ADR $ONC
Temasek Holdings Private Ltd bought a new position in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the second quarter, according to its most recent Form 13F filing with the...
MarketBeat·5d ago
News Placeholder
Nan Fung Group Holdings Ltd Makes New $3.81 Million Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC
Nan Fung Group Holdings Ltd acquired a new stake in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F...
MarketBeat·5d ago
News Placeholder
BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating...
Benzinga·5d ago
News Placeholder
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating...
Business Wire·5d ago
News Placeholder
BeOne Medicines (NASDAQ:ONC) Stock Price Down 4.8% - What's Next?
BeOne Medicines (NASDAQ:ONC) Trading Down 4.8% - What's Next...
MarketBeat·6d ago
News Placeholder
7,707 Shares in BeOne Medicines Ltd. - Sponsored ADR $ONC Bought by Tema Etfs LLC
Tema Etfs LLC bought a new stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·7d ago
News Placeholder
Walleye Capital LLC Purchases Shares of 36,645 BeOne Medicines Ltd. - Sponsored ADR $ONC
Walleye Capital LLC acquired a new position in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·7d ago
News Placeholder
3,330 Shares in BeOne Medicines Ltd. - Sponsored ADR $ONC Bought by Qtron Investments LLC
Qtron Investments LLC bought a new stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm...
MarketBeat·7d ago

Latest ONC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.